Anebulo Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Anebulo Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|
| research and development | 748,339 | 1,062,672 | 1,270,220 |
| general and administrative | 915,912 | 1,697,787 | 1,273,458 |
| total operating expenses | 1,664,251 | 2,760,459 | 2,543,678 |
| income from operations | -1,664,251 | -2,760,459 | -2,543,678 |
| yoy | |||
| qoq | -39.71% | 8.52% | |
| operating margin % | |||
| other incomes: | |||
| interest expense | 59,696 | 31,838 | |
| interest income | -68,084 | -75,522 | -55,198 |
| other | -2,321 | 594 | -7,657 |
| other income | -10,709 | ||
| net income | -1,653,542 | -2,717,369 | -2,480,823 |
| yoy | |||
| qoq | -39.15% | 9.53% | |
| net income margin % | |||
| weighted-average common shares outstanding, basic and diluted | 25,933,217 | 25,789,739 | 25,633,217 |
| net income per share | -0.06 | -0.11 | -0.1 |
| other incomes | -43,090 | ||
| total other incomes | -62,855 |
We provide you with 20 years income statements for Anebulo Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Anebulo Pharmaceuticals stock. Explore the full financial landscape of Anebulo Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Anebulo Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.